Panretin(alitretinoin)
Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. It has been approved in Europe to treat kaposi sarcoma. The pharmaceutical is active against retinoic acid receptor beta, vitamin K epoxide reductase complex subunit 1, retinoic acid receptor gamma, and retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor RXR-beta, retinoic acid receptor RXR-gamma, and retinoic acid receptor RXR-alpha.
...
More
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Panretin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alitretinoin
Tradename
Company
Number
Date
Products
PANRETINADVANZ PHARMAN-020886 RX1999-02-02
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
panretinNew Drug Application2024-12-05
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
skin diseasesD012871L00-L99
kaposi sarcomaD012514C46
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D11: Other dermatological preparations in atc
D11A: Other dermatological preparations in atc
D11AH: Agents for dermatitis, excluding corticosteroids
D11AH04: Alitretinoin
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XF: Retinoids for cancer treatment
L01XF02: Alitretinoin
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DermatitisD003872L30.9314
Atopic dermatitisD003876EFO_0000274L2011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EczemaD004485L30.9156
NeuroblastomaD009447EFO_0000621123
Skin diseasesD012871L00-L9933
Hand dermatosesD00622933
Breast neoplasmsD001943EFO_0003869C50112
Male breast neoplasmsD01856711
Lamellar ichthyosisD017490Q8011
IchthyosisD007057E50.811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver failureD017093K72.91112
Hepatic insufficiencyD0485501112
SarcomaD012509112
Hiv infectionsD015658EFO_0000764B20112
Kaposi sarcomaD012514C46112
LeukemiaD007938C95111
Myelomonocytic leukemia juvenileD054429C93.3111
Lichen planusD008010L4311
Systemic lupus erythematosusD008180EFO_0002690M3211
Cutaneous lupus erythematosusD008178EFO_0003834L93.111
Show 3 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlitretinoin
INNalitretinoin
Description
9-cis-retinoic acid is a retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry. It has a role as an antineoplastic agent, a retinoid X receptor agonist, a metabolite and a keratolytic drug. It is a conjugate acid of a 9-cis-retinoate.
...
More
Classification
Small molecule
Drug classretinol derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Identifiers
PDB
CAS-ID5300-03-8
RxCUI
ChEMBL IDCHEMBL705
ChEBI ID50648
PubChem CID449171
DrugBankDB00523
UNII ID1UA8E65KDZ (ChemIDplus, GSRS)
Target
Agency Approved
RARB
RARB
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Alternate
RXRG
RXRG
RXRB
RXRB
Organism
Homo sapiens
Gene name
RXRG
Gene synonyms
NR2B3
NCBI Gene ID
Protein name
retinoic acid receptor RXR-gamma
Protein synonyms
Nuclear receptor subfamily 2 group B member 3, Retinoid X receptor gamma
Uniprot ID
Mouse ortholog
Rxrg (20183)
retinoic acid receptor RXR-gamma (P28705)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 835 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
93 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use